Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.53 |
| ▸ | ACACB | O00763 | 1/20 | 0.52 |
| ▸ | ACACA | Q13085 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 7/20 | 0.45 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.42 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemcabene SCHEMBL528316 | 1.00 | ACLY (0.53) | ACLYACACBACACAPPARATTR | |
| Gemcabene SCHEMBL761631 | 0.98 | ACLY (0.55) | ACLYACACBACACAPPARATTR | |
| SCHEMBL14269711 | 0.96 | ACLY (0.59) | ACLYACACBACACAPPARATTR | |
| SCHEMBL5524941 | 0.96 | ACLY (0.59) | ACLYACACBACACAPPARATTR | |
| SCHEMBL5531453 | 0.96 | ACLY (0.59) | ACLYACACBACACAPPARATTR | |
| SCHEMBL6258161 | 0.96 | ACLY (0.53) | ACLYACACBACACAPPARATTR | |
| SCHEMBL5521484 | 0.94 | ACLY (0.57) | ACLYACACBACACAPPARATTR | |
| SCHEMBL6267270 | 0.94 | ACLY (0.52) | ACLYACACBACACAPPARATTR | |
| SCHEMBL13210381 | 0.92 | ACLY (0.50) | ACLYACACBACACAPPARATTR | |
| SCHEMBL5528996 | 0.91 | ACLY (0.52) | ACLYACACBACACAPPARATTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140012042-A1 | Calcium Dicarboxylate Ethers | WARNER-LAMBERT COMPANY, LLC (US) | 2014-01-09 | — | — | US | disclosed |
| US-8557835-B2 | Statin-carboxyalkylether combinations | WARNER-LAMBERT COMPANY, LLC (US) | 2013-10-15 | — | — | US | disclosed |
| US-20090118317-A1 | Statin-Carboxyalkylether Combinations | PFIZER INC. | 2009-05-07 | — | — | US | disclosed |
| US-20050148654-A1 | Statin-carboxyalkylether combinations | BISGAIER CHARLES L (US) | 2005-07-07 | — | — | US | disclosed |
| EP-1045691-B1 | STATIN-CARBOXYALKYLETHER COMBINATIONS | WARNER LAMBERT CO (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-1481962-A1 | New cholesterolemia-lowering carboxyalkylether compound | Warner-Lambert Company LLC (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20030105154-A1 | Statin-carboxyalkylether combinations | BISGAIER CHARLES LARRY (US) | 2003-06-05 | — | — | US | disclosed |
| US-20020103252-A1 | Statin-carboxyalkylether combinations | BISGAIER CHARLES LARRY (US) | 2002-08-01 | — | — | US | disclosed |
| EP-1045691-A1 | STATIN-CARBOXYALKYLETHER COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999030704-A1 | STATIN-CARBOXYALKYLETHER COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105154-A1 | Statin-carboxyalkylether combinations | HMGCR, CETP, LCAT | ACLY 436/4885ACACB 29/4885ACACA 26/4885 |
| US-20140012042-A1 | Calcium Dicarboxylate Ethers | CETP, HMGCR, LCAT | ACLY 566/4885ACACB 25/4885ACACA 7/4885 |
| US-20020103252-A1 | Statin-carboxyalkylether combinations | HMGCR, CETP, LCAT | ACLY 436/4885ACACB 29/4885ACACA 26/4885 |
| US-20050148654-A1 | Statin-carboxyalkylether combinations | HMGCR, CETP, LCAT | ACLY 436/4885ACACB 29/4885ACACA 26/4885 |
| US-20090118317-A1 | Statin-Carboxyalkylether Combinations | HMGCR, CETP, LCAT | ACLY 436/4885ACACB 29/4885ACACA 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.